Higher Doses of Oral Propranolol for Resistant Infantile Haemangiomas
Acta Dermato-Venereologica · 2026
DOI: 10.2340/actadv.v106.43152 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Dermato-Venereologica, 2026. Verfasst von Isabelle Dreyfus und 11 weiteren Autor:innen. Beteiligte Einrichtung: Reference Center for rare diseases of the skin, CHU Toulouse Larrey, Toulouse, France. dreyfus.i@chu-toulouse.fr. Hauptthemen laut MEDLINE: Propranolol, Drug Resistance, Neoplasm, Adrenergic beta-Antagonists, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Propranolol at 3 mg/kg/day is considered the gold standard for treating infantile haemangiomas. Nevertheless, the management of propranolol-resistant infantile haemangiomas (PRIH) remains challenging. This national multicentre retrospective observational study includes all PRIHs who received propranolol > 3 mg/kg/day. The study aims to investigate the pattern of PRIHs, assess the effects and tolerance of a higher dose, and identify predictive factors for response to this increased dosage. Fifteen PRIHs were included (prevalence 0.45%), mainly females, and most presented with a large lesion. Three distinct patterns of PRIH were identified: facial segmental lesions (47%), facial localized lesions with a subcutaneous component (40%), and body-localized mixed and ulcerated lesions (13%). Six PRIH (40%) responded to the higher dose (from 3.75 to 4 mg/kg/day). Three predictive factors were significantly associated with a good response: IGIc-IH1 at the end of 3 mg/kg/day regimen (OR = 22.9, 95% CI [1.2–1844.1]), a duration of 3.5 months or more at 3 mg/kg/day (OR = 17.5, 95% CI [1.22–250.37]), and 7 months or more at > 3 mg/kg/day (OR = 17.5, 95% CI [1.22–250.37]). Tolerance was generally good, although one patient experienced severe hypotension during dose escalation. Propranolol doses higher than 3 mg/kg/day may therefore be considered a potential treatment option for PRIHs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Reference Center for rare diseases of the skin, CHU Toulouse Larrey, Toulouse, France. dreyfus.i@chu-toulouse.fr.
- Reference Center for rare diseases of the skin, CHU Toulouse Larrey, Toulouse, France.
- Dermatology Department, Necker Children's Hospital, Assistance publique-hôpitaux de Paris, Paris, France.
- Department of Dermatology, Nantes Université, Nantes, France.
- Dermatology Cabinet, Nantes, France.
- Department of Dermatology, Unit of Pediatric Dermatology, University of Tours, Inserm 1246-SPHERE, CHRU Tours, Tours, France.
Zitieren
APA
Dreyfus, I., Dénos, C., Boccara, O., Barbarot, S., Gagey-Caron, V., Maruani, A., Miquel, J., Droitcourt, C., Bigorre, M., Martin, L., Leauté-Labrèze, C., & Mazereeuw-Hautier, J. (2026). Higher Doses of Oral Propranolol for Resistant Infantile Haemangiomas. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v106.43152
Vancouver
Dreyfus I, Dénos C, Boccara O, Barbarot S, Gagey-Caron V, Maruani A, et al. Higher Doses of Oral Propranolol for Resistant Infantile Haemangiomas. Acta Dermato-Venereologica. 2026. doi:10.2340/actadv.v106.43152
BibTeX
@article{Dreyfus2026,
author = {Dreyfus, Isabelle and Dénos, Charlène and Boccara, Olivia and Barbarot, Sébastien and Gagey-Caron, Véronique and Maruani, Annabel and Miquel, Juliette and Droitcourt, Catherine and Bigorre, Michèle and Martin, Ludovic and Leauté-Labrèze, Christine and Mazereeuw-Hautier, Juliette},
title = {Higher Doses of Oral Propranolol for Resistant Infantile Haemangiomas},
journal = {Acta Dermato-Venereologica},
year = {2026},
doi = {10.2340/actadv.v106.43152}
}
EUVIMED